HPV Testing with Hybrid Capture 2 (HC2) Technology

The digene HPV Test — preventing cervical cancer

Worldwide, cervical cancer affects approximately 500,000 women annually and, after breast cancer, is the second-most-common maligancy found in women. Human papillomavirus (HPV) infection is linked to cervical cancer, and women who have HPV infection can be identified. Cervical cancer risk is highly preventable and treatable.

The digene HPV Test (digene HC2 High-Risk HPV DNA Test and digene HC2 HPV DNA Test) has been approved in Europe and the United States since 1999. More than 300 peer-reviewed journal articles have data generated with the digene HC2 High-Risk HPV DNA Test, and the test has been studied in international clinical trials involving over 1 million women worldwide. The digene HPV Test is the world's most proven HPV test for sensitive, early detection of cervical cancer and disease. The digene HC2 High-Risk HPV DNA Test is CE-marked for testing for high-risk types of HPV.

Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.